Skip to main content

Table 1 MAb/PAb reactions against DENV NS1 glycoproteins and the RLX1 peptide

From: Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies

Antibodya

Epitope (motif)b

1/log1050% end-point ELISA titrec

Immunoblot reactions against non-reduced NS1 glycoproteinsd

D2V NS1 glycoprotein

RLX1 peptide

D1V

D2V

D3V

D4V

MAb

       

1H7.4

LD2

6.0

<1.5

++++

++++

  

5H4.3

24A

5.2

<1.5

+++

+++

++

++

3D1.4

LX1

5.4

4.7

+++

+++

+++

+++

1G5.3

24C

5.7

<1.5

+++

+++

+

+++

1C6.3

(KELK/KLEK)

4.5

1.7

+++

++

++

+++

1G5.4-A1-C3

(ELK/KLE)

5.2

1.9

++

++++

+

+++

PAb (Haplotype)

       

C57BL/BJ (I-Ab)

Multiple

4.5

2.9

+++

+++

++

+++

B10.S (I-As)

Multiple

4.7

3.0

++

+++

++

+++

B10.RIII (I-Ar, I-Er)

Multiple

3.8

2.2

+

++

+

+

B10.BR (I-Ak,I-Ak)

Multiple

3.7

2.0

++

++

+

+

B10.G (I-Aq)

Multiple

4.0

2.1

++

++

  

B10.D2N (I-Ad,I-Ed)

Multiple

4.0

2.1

+

+

 

+

B10.A (I-Ak)

Multiple

3.5

1.7

+

+

  

B10.S (C) I-As)

Multiple

<1.0

<1.5

    
  1. aMonoclonal antibodies (MAbs) or polyclonal antibodies (PAbs) generated against the native hexameric.
  2. DENV-2 NS1 glycoprotein or control protein (ovalbumin) (B10.S (C)) in congeneic mouse strains with the H2 class II (I-E and/or I-A molecule) haplotypes shown in brackets.
  3. bEpitope name or reaction with multiple epitopes (PAbs), or MAbs which defined multiple ELK/KLE-type and KELK/KLEK-type motifs in multiple peptide sequences from the DENV-2 NS1 glycoprotein.
  4. cReciprocal log10 50% end-point ELISA titers against immuno-affinity purified native hexameric DENV-2 (D2V) s/eNS1 glycoprotein and the RLX1 synthetic peptide.
  5. dImmunoblot colour reaction intensity gauged on an arbitrary scale from negative (blank) to ++++ against the non-reduced NS1 glycoproteins of DENV-1 (D1V) to DENV-4 (D4V).